Cited by 159Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchDiabetes and associated disorders

Use of HbA1c in Predicting Progression to Diabetes in French Men and Women

Open access
Droumaguet, Celine, Balkau, Beverley, Simon, Dominique, Caces, Emile, Tichet, Jean, Charles, Marie Aline, Eschwege, Eveline, the DESIR Study Group·2006·Diabetes Care

Abstract

OBJECTIVE—Early identification of subjects at high risk for diabetes is essential, and random HbA1c (A1C) may be more practical than fasting plasma glucose (FPG). The predictive value of A1C, in comparison to FPG, is evaluated for 6-year incident diabetes. RESEARCH DESIGN AND METHODS—From the French cohort study Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR), 1,383 men and 1,437 women, aged 30–65 years, were volunteers for a routine health check-up. Incident diabetes was defined by FPG ≥7.0 mmol/l or treatment by antidiabetic drugs. Multivariate logistic regression models were used to predict diabetes at 6 years. Receiver operating characteristic curves compared the predictive values of A1C and FPG. RESULTS—At 6 years, 30 women (2.1%) and 60 men (4.3%) had developed diabetes. Diabetes risk increased exponentially with A1C in both sexes (P < 0.001). After stratifying on FPG, A1C predicted diabetes only in subjects with impaired fasting glucose (IFG) (FPG ≥6.10 mmol/l): the odds ratio (95% CI) for a 1% increase in A1C was 7.20 (3.00–17.00). In these subjects, an A1C of 5.9% gave an optimal sensitivity of 64% and specificity of 77% to predict diabetes. CONCLUSIONS—A1C predicted diabetes, even though the diagnosis of diabetes was based on FPG, but it was less sensitive and specific than FPG. It could be used as a test if fasting blood sampling was not available or in association with FPG. In subjects with IFG, A1C is better than glucose to evaluate diabetes risk, and it could be used to select subjects for intensive early intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc05-2525

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Droumaguet, C., Balkau, B., Simon, D., Caces, E., Tichet, J., Charles, M. A., Eschwege, E., & the DESIR Study Group
Affiliations
  • Institut National de la Santé et de la Recherche Médicale U258, Villejuif, France
  • Université Paris-Sud (FR)
  • Institut inter-Régional pour la Santé, La Riche, France
Venue
Diabetes Care
Published
2006-07-01
Volume
29
Issue
7
Pages
1619-1625
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2111141578
Cited by
159
References
32
Citations by year
2025: 4 · 2024: 1 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 7 · 2018: 7 · 2017: 7 · 2016: 13 · 2015: 13 · 2014: 5 · 2013: 14 · 2012: 15
FWCI
4.44
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Eli Lilly and Company
  • Les Laboratories Pierre Fabre
  • Institut National de la Santé et de la Recherche Médicale
  • Novo Nordisk
  • Fondation de France
  • Novartis Pharma
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
HbA1c, new-onset diabetes, diabetes risk prediction, fasting blood glucose, impaired fasting glucose, DESIR cohort, sex differences, sensitivity and specificity, early detection of diabetes
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Female, France, Glycated Hemoglobin, Humans, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Sensitivity and Specificity, Incidence, Logistic Models, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review